|Mr. J. Scott Wolchko||Founder, CEO, President & Director||645k||3.85M||1970|
|Mr. Edward J. Dulac III||Chief Financial Officer||455k||N/A||1976|
|Ms. Cindy R. Tahl||General Counsel & Corporate Secretary||455k||3.89M||1973|
|Dr. Bahram Valamehr Ph.D.||Chief Research & Development Officer||455k||1.39M||1977|
|Mr. Jim Beitel M.B.A.||Senior Vice President of Corporate Development||N/A||N/A||N/A|
|Dr. Jerome Bressi Ph.D.||Senior Vice President of Regulatory & Quality||N/A||N/A||N/A|
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Fate Therapeutics, Inc.’s ISS Governance QualityScore as of November 28, 2023 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 8; Compensation: 7.